Guggenheim Reiterates Buy on Spyre (SYRE) Amidst Trial Shifts

Font: Financial Modeling Prep  • Aug 27, 2026

Guggenheim Reiterates Buy Rating for Spyre Therapeutics (NASDAQ: SYRE) Amidst Clinical Trial Shifts

• Leading analyst firm Guggenheim maintains a Buy rating for Spyre Therapeutics despite a recent decline in its biotech stock price.
• Mixed Phase II clinical trial results for SPY072 in rheumatoid arthritis (RA) have prompted Spyre Therapeutics to strategically shift its focus towards other autoimmune conditions and combination therapies.
• Spyre Therapeutics boasts a strong financial position with approximately $1.15 billion in cash, projected to fund operations into late 2029, but faces a high valuation and growing competition in the biopharmaceutical market.

Leading analyst firm Guggenheim reiterates its Buy rating for biotechnology stock Spyre Therapeutics (NASDAQ: SYRE). At the time of the rating, the biotech stock price was $93.61. Spyre Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for inflammatory and autoimmune diseases, conditions where the body's immune system mistakenly attacks its own tissues.

Despite the positive analyst rating, Spyre Therapeutics' stock price recently declined following mixed results from its Phase II SKYWAY study. The clinical trial evaluated its investigational drug SPY072 in patients with rheumatoid arthritis (RA). SPY072 is an antibody designed to target the TL1A protein, a key mediator of inflammation.

As highlighted by Benzinga, the trial data indicated that SPY072 was safe and demonstrated symptom improvement. However, the clinical trial results did not fully meet Spyre Therapeutics' internal efficacy goals for SPY072 as a standalone rheumatoid arthritis therapy. Consequently, the biotech company is now strategically shifting its focus for SPY072 toward other autoimmune conditions and combination therapies.

Supporting the analyst's positive investment outlook, Spyre Therapeutics maintains a strong financial position. A report from Zacks Investment Research highlights the company's substantial cash reserves of approximately $1.15 billion. This cash runway is projected to fund its operations and multiple clinical trials into late 2029, providing significant financial stability for its drug development pipeline.

However, Zacks also points out that Spyre Therapeutics currently has no marketed products or commercial revenues. The biotech firm faces a high valuation and growing competition from other major drugmakers, including Johnson & Johnson (NYSE: JNJ). Its investment case heavily relies on future clinical success from its diverse drug pipeline, which targets inflammatory bowel disease and other autoimmune conditions.